Synthesis and opioid receptor binding of indium (III) and [111In]-labeled macrocyclic conjugates of diprenorphine: novel ligands designed for imaging studies of peripheral opioid receptors.

about

Synthesis and opioid receptor binding of indium (III) and [111In]-labeled macrocyclic conjugates of diprenorphine: novel ligands designed for imaging studies of peripheral opioid receptors.

Item

http://www.wikidata.org/entity/Q41904743

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Synthesis and opioid receptor ...... f peripheral opioid receptors.

@en

type

Item

label

Synthesis and opioid receptor ...... f peripheral opioid receptors.

@en

prefLabel

Synthesis and opioid receptor ...... f peripheral opioid receptors.

@en

P1476

Synthesis and opioid receptor ...... f peripheral opioid receptors.

@en

P2093

Emily A Fergason-Cantrell

http://www.w3.org/2001/XMLSchema#string

John R Lever

http://www.w3.org/2001/XMLSchema#string

Roger I Nahas

http://www.w3.org/2001/XMLSchema#string

Shefali Srivastava

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of the human κ-opioid receptor in complex with JDTic

Opioid-induced constipation: advances and clinical guidance

Recent developments in the study of opioid receptors

Crystal structure of the µ-opioid receptor bound to a morphinan antagonist

Structure of the δ-opioid receptor bound to naltrindole

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?

Novel analgesics and molecular rearrangements in the morphine-thebaine group. 3. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine.

The orvinols and related opioids--high affinity ligands with diverse efficacy profiles.

New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.

P304

6127-6135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TET.2016.08.015

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28190898

http://www.w3.org/2001/XMLSchema#string

P932

5298243

http://www.w3.org/2001/XMLSchema#string